Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 701 in relapsed/refractory multiple myeloma
NCT03287908Phase 1Terminated
- Sponsor
- Amgen
- Start
- Nov 2017
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of pavurutamab in multiple myeloma (MM) (3 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 60 months and 6 more. Started Nov 2017; status: terminated.
02
Drugs
pavurutamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03287908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287908.